Replies to post #12681 on Momenta Pharmaceuticals, Inc. (MNTA)

[DFRAI]

Dew - what is your opinion

MNTA has stated that they have:
- 2 molecules partnered with Baxter and that they have a suite of
- 6 additional biosimilars in early development based on CHO, SB2 and NS0 cell lines.

So Baxter could chose additional biosimilars from these 6 programs and they could potentially partner some out

Additionally they have:
- NEcuparanib,
- Copaxone and
- 3 additional programs in Ivg, SIF3 and anti-FcRn

This is a full plate for such a small company, very bright future if Copaxone would given them revenue for the next 3 years to push forward.

What do you think about Necuparanib vs Puma Biotechnology which has only one cancer molecule and its worth 7 billion dollars in market cap?